114 related articles for article (PubMed ID: 12691780)
1. The neurochemical effects of anxiolytic drugs are dependent on rearing conditions in Fawn-Hooded rats.
Lodge DJ; Lawrence AJ
Prog Neuropsychopharmacol Biol Psychiatry; 2003 May; 27(3):451-8. PubMed ID: 12691780
[TBL] [Abstract][Full Text] [Related]
2. The CRF1 receptor antagonist, antalarmin, reverses isolation-induced up-regulation of dopamine D2 receptors in the amygdala and nucleus accumbens of fawn-hooded rats.
Djouma E; Card K; Lodge DJ; Lawrence AJ
Eur J Neurosci; 2006 Jun; 23(12):3319-27. PubMed ID: 16820021
[TBL] [Abstract][Full Text] [Related]
3. Analysis of strain difference in behavior to Cholecystokinin (CCK) receptor mediated drugs in PVG hooded and Sprague-Dawley rats using elevated plus-maze test apparatus.
Farook JM; Zhu YZ; Wang Q; Moochhala SM; Lee L; Wong PT
Neurosci Lett; 2004 Apr; 358(3):215-9. PubMed ID: 15039119
[TBL] [Abstract][Full Text] [Related]
4. The effect of isolation rearing on volitional ethanol consumption and central CCK/dopamine systems in Fawn-Hooded rats.
Lodge DJ; Lawrence AJ
Behav Brain Res; 2003 May; 141(2):113-22. PubMed ID: 12742247
[TBL] [Abstract][Full Text] [Related]
5. Behavioral and neurochemical effects on rat offspring after prenatal exposure to ethanol.
Carneiro LM; Diógenes JP; Vasconcelos SM; Aragão GF; Noronha EC; Gomes PB; Viana GS
Neurotoxicol Teratol; 2005; 27(4):585-92. PubMed ID: 16039829
[TBL] [Abstract][Full Text] [Related]
6. The effect of chronic ethanol consumption and withdrawal on mu-opioid and dopamine D(1) and D(2) receptor density in Fawn-Hooded rat brain.
Djouma E; Lawrence AJ
J Pharmacol Exp Ther; 2002 Aug; 302(2):551-9. PubMed ID: 12130715
[TBL] [Abstract][Full Text] [Related]
7. The effect of chronic CRF1 receptor blockade on the central CCK systems of Fawn-Hooded rats.
Lodge DJ; Lawrence AJ
Regul Pept; 2003 Nov; 116(1-3):27-33. PubMed ID: 14599712
[TBL] [Abstract][Full Text] [Related]
8. Different pathways mediated by CCK1 and CCK2 receptors: effect of intraperitonal mrna antisense oligodeoxynucleotides to cholecystokinin on anxiety-like and learning behaviors in rats.
Cohen H; Kaplan Z; Matar MA; Buriakovsky I; Bourin M; Kotler M
Depress Anxiety; 2004; 20(3):139-52. PubMed ID: 15487014
[TBL] [Abstract][Full Text] [Related]
9. [Behavioral and neurochemical study on the role of the brain cholecystokinin system in anxiety].
Izumi T
Hokkaido Igaku Zasshi; 1998 Sep; 73(5):463-73. PubMed ID: 9846276
[TBL] [Abstract][Full Text] [Related]
10. Cholecystokinin-2 (CCK2) receptor-mediated anxiety-like behaviors in rats.
Wang H; Wong PT; Spiess J; Zhu YZ
Neurosci Biobehav Rev; 2005; 29(8):1361-73. PubMed ID: 16120463
[TBL] [Abstract][Full Text] [Related]
11. Chronic corticotropin-releasing factor type 1 receptor antagonism with antalarmin regulates the dopaminergic system of Fawn-Hooded rats.
Lawrence AJ; Parish CL; Chen F; Lodge DJ; Krstew EV; Card K; Finkelstein DI; Horne MK
J Neurochem; 2005 Sep; 94(6):1523-34. PubMed ID: 16000149
[TBL] [Abstract][Full Text] [Related]
12. Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity.
Hughes J; Boden P; Costall B; Domeney A; Kelly E; Horwell DC; Hunter JC; Pinnock RD; Woodruff GN
Proc Natl Acad Sci U S A; 1990 Sep; 87(17):6728-32. PubMed ID: 1975695
[TBL] [Abstract][Full Text] [Related]
13. Anxiolytic effects of CCK-B antagonists.
Costall B; Domeney AM; Hughes J; Kelly ME; Naylor RJ; Woodruff GN
Neuropeptides; 1991 Jul; 19 Suppl():65-73. PubMed ID: 1679211
[TBL] [Abstract][Full Text] [Related]
14. Characterisation of the selective 5-HT1B receptor antagonist SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)-2,3-dihydro-5-methoxyindol-1-yl]-1-[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methanone hydrochloride): in vivo neurochemical and behavioural evidence of anxiolytic/antidepressant activity.
Dawson LA; Hughes ZA; Starr KR; Storey JD; Bettelini L; Bacchi F; Arban R; Poffe A; Melotto S; Hagan JJ; Price GW
Neuropharmacology; 2006 Jun; 50(8):975-83. PubMed ID: 16581092
[TBL] [Abstract][Full Text] [Related]
15. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: III. Actions in models of potential antidepressive and anxiolytic activity in comparison with ropinirole.
Millan MJ; Brocco M; Papp M; Serres F; La Rochelle CD; Sharp T; Peglion JL; Dekeyne A
J Pharmacol Exp Ther; 2004 Jun; 309(3):936-50. PubMed ID: 14978196
[TBL] [Abstract][Full Text] [Related]
16. The behavioural properties of CI-988, a selective cholecystokininB receptor antagonist.
Singh L; Field MJ; Hughes J; Menzies R; Oles RJ; Vass CA; Woodruff GN
Br J Pharmacol; 1991 Sep; 104(1):239-45. PubMed ID: 1686205
[TBL] [Abstract][Full Text] [Related]
17. The metabotropic glutamate 5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]-pyridine reduces ethanol self-administration in multiple strains of alcohol-preferring rats and regulates olfactory glutamatergic systems.
Cowen MS; Djouma E; Lawrence AJ
J Pharmacol Exp Ther; 2005 Nov; 315(2):590-600. PubMed ID: 16014750
[TBL] [Abstract][Full Text] [Related]
18. Suppression of conditioned fear by administration of CCKB receptor antagonist PD135158.
Tsutsumi T; Akiyoshi J; Isogawa K; Kohno Y; Hikichi T; Nagayama H
Neuropeptides; 1999 Dec; 33(6):483-6. PubMed ID: 10657528
[TBL] [Abstract][Full Text] [Related]
19. Role of spinal cholecystokinin in neuropathic pain after spinal cord hemisection in rats.
Kim J; Kim JH; Kim Y; Cho HY; Hong SK; Yoon YW
Neurosci Lett; 2009 Oct; 462(3):303-7. PubMed ID: 19619609
[TBL] [Abstract][Full Text] [Related]
20. The NK1 receptor antagonist NKP608 lacks anxiolytic-like activity in Swiss-Webster mice exposed to the elevated plus-maze.
Rodgers RJ; Gentsch C; Hoyer D; Bryant E; Green AJ; Kolokotroni KZ; Martin JL
Behav Brain Res; 2004 Sep; 154(1):183-92. PubMed ID: 15302124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
